Co-Authors
This is a "connection" page, showing publications co-authored by KHANDAN KEYOMARSI and SAID AKLI.
Connection Strength
3.238
-
Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle. 2012 Apr 01; 11(7):1468-76.
Score: 0.416
-
Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 2011 May 01; 71(9):3377-86.
Score: 0.386
-
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010 Feb 15; 16(4):1179-90.
Score: 0.359
-
Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res. 2007 Aug 01; 67(15):7212-22.
Score: 0.301
-
Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res. 2004; 6(5):188-91.
Score: 0.243
-
Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 2004 May 01; 64(9):3198-208.
Score: 0.240
-
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis. Mol Cancer Ther. 2024 Apr 02; 23(4):492-506.
Score: 0.239
-
Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S38-47.
Score: 0.227
-
LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 2021 May 14; 10(5):40.
Score: 0.196
-
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol. 2016 07; 186(7):1900-1912.
Score: 0.138
-
The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015 Jul; 34(27):3556-67.
Score: 0.123
-
Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res. 2013 Sep 01; 73(17):5556-68.
Score: 0.114
-
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538.
Score: 0.104
-
Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol. 2006 Dec; 209(3):686-94.
Score: 0.072
-
The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003 Sep-Oct; 2(5):461-6.
Score: 0.057
-
A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 08; 29(27):3896-907.
Score: 0.023